Surface warns bankruptcy possible if shareholders reject Coherus merger

Surface Oncology has shown investors the ghost of biotech yet to come. Needing shareholder support for its planned merger with Coherus BioSciences, the biotech has warned that outlays triggered by the deal have shrunk its cash runway and will leave Surface needing funding fast if the deal collapses.